This segment focuses on the development, commercialization, and marketing of treatments for Attention Deficit Hyperactivity Disorder (ADHD). Key products include Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER, which are designed to address the needs of patients aged 6 and older. Research and development activities include clinical trials to assess efficacy and safety, as well as formulation improvements. The company utilizes advanced pharmaceutical technologies to ensure effective drug delivery and patient compliance. The segment aims to improve the lives of individuals with ADHD by providing accessible and effective medication options. Market positioning involves targeting healthcare providers and patients through strategic sales and marketing initiatives. Future opportunities include expanding the product portfolio and exploring new indications. Regulatory aspects involve obtaining and maintaining FDA approvals and adhering to all relevant guidelines. Partnerships may include collaborations with healthcare professionals and patient advocacy groups.

This segment encompasses the commercialization of prescription pediatric products acquired through the acquisition of Cerecor, Inc.'s pediatric portfolio. This includes products like Karbinal ER, a carbinoxamine oral suspension for allergies, and Poly-Vi-Flor and Tri-Vi-Flor supplements for fluoride deficiency. The segment focuses on providing essential healthcare solutions for children. Research and development efforts may involve formulation improvements and exploring new applications for existing products. The segment leverages established distribution channels and relationships with pediatricians to reach its target market. The patient impact is significant, as these products address common pediatric health needs. Market positioning involves competing with established brands in the pediatric pharmaceutical space. Future opportunities include expanding the product line and exploring new partnerships. Regulatory compliance is crucial, with adherence to FDA guidelines and pediatric-specific regulations. The segment may involve collaborations with healthcare providers and pharmacies.

This segment focuses on the commercialization of products for insomnia and cough/cold symptoms. Key products include ZolpiMist, an oral spray for insomnia, and Tuzistra XR, a prescription antitussive. Research and development activities may involve exploring new formulations and delivery methods to improve patient outcomes. The segment utilizes established sales and marketing channels to reach healthcare providers and patients. The patient impact is significant, as these products address common health concerns. Market positioning involves competing with established brands in the insomnia and cough/cold markets. Future opportunities include expanding the product portfolio and exploring new partnerships. Regulatory compliance is crucial, with adherence to FDA guidelines and relevant regulations. Partnerships may include collaborations with healthcare providers and pharmacies.